BASILEA N overview

Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2023. At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the US Food and Drug Administration (FDA) approved ZEVTERA ® (ceftobiprole medocaril sodium for injection), for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB),...

Increased Cresemba ® and Zevtera ® -related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidance Operating profit of CHF 19.2 million and net profit of CHF 10.5 million, significantly above guidance Addition of three new anti-infective assets to clinical portfolio, including phase-3-ready antifungal fosmanogepix Strong cash and restricted cash position of CHF 64.3 million, after fully absorbing investments into portfolio expansion and accelerated debt reduction FY 2024...

Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the sales of the antifungal Cresemba ® (isavuconazole) in 2023 by its partner Knight Therapeutics Inc. (“Knight”, TSX: GUD) in Latin America exceeded the threshold triggering the first sales milestone payment for this region. David Veitch, Chief...

Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strains Allschwil, Switzerland, January 15, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Spexis AG (SIX: SPEX) for a...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it will accelerate the repayment of its senior secured loan. The senior secured loan from Athyrium Capital Management, LP (“Athyrium”) had an initial total amount of CHF 75 million and a two-year term from...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. In...

New compound added to Basilea’s clinical pipeline; upon successful completion of preclinical profiling, start of phase 2 study planned for H1 2025 Upfront payments of USD 2 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 19, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset...